Dr Nicholas Jonhson, new Chief Medical Advisor

August 2020:

After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1,  associate professor of Neurology and Human and Molecular Genetics, vice chair of research in Neurology at Virginia Commonwealth University and co-principal investigator of the Myotonic Dystrophy Clinical Research Network.

The co-founder and CEO of the company, Dr. Beatriz Llamusí welcomes Dr. Johnson and emphasizes his experience to consolidate the ARTHEx’s project. “Dr. Johnson is a KoL in DM1 with a strong experience on therapeutic trials in DM1 and many other inherited nerve and muscle disorders. Undoubtedly, he will play a crucial role in the design and execution of the clinical development of our therapy.”

“I am excited to assist ARTHEx in the development of novel, precision-based therapies for DM1. They have assembled a dedicated team focused on treating DM1, and have a therapy with a unique mechanism of action. I hope that we can bring this forward for our patients.” said Nicholas Johnson, M.D., M.Sci., FAAN.

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Funding will help advance development of company’s Myotonic Dystrophy therapy

Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed a funding round of €4.25 million ($4.9M). This round completes an initial seed round of €2.7 million ($3.1M) brought by Invivo and CDTI-Innvierte in December 2019 and in June 2020 respectively. The total funds raised by Arthex since inception are now €6.95 million ($8M).

pdf iconWith the new funding provided by Advent France Biotechnology (AFB) and Invivo Ventures, Arthex can ensure that its therapy will be first-in-human trial ready by 2022; on completion of the ongoing optimization of the drug candidate and subsequent preclinical regulatory studies.

Arthex Team in Valencia

International Myotonic Dystrophy Consortium

Challenges in Myotonic Dystrophy

June 2019:

The ARTHEx Biotech team at the International Myotonic Dystrophy Consortium held from 10 to 14 June 2019 in Gothenburg, Sweden. “Challenges in Myotonic Dystrophy – from basic science to therapy”.

International Myotonic Dystrophy Consortium


Beatriz Llamusi and Arthex Biotech


37th Annual J. P. Morgan Healthcare Conference

January 2019:

ARTHEx S.L. participation at the 37th Annual J.P. Morgan Healthcare Conference, celebrated from January 7 to 10 2019 in San Francisco, California.

Participation at the 37th Annual J. P. Morgan

BIO International Convention

Meeting of the international biotechnology

June 2018:

ARTHEx S.L. participation at the BIO International Convention, the most important partnering meeting of the international biotechnology sector, which took place from June 4 to 7 2018 in Boston, Massachusetts.

BIO International Convention

Partnering meeting of the international biotechnology sector




Investors and Venture Capitals health innovation projects

March 2018:

The “Fundación para la Innvación y la Prospectiva en Salud en España” (FIPSE), presents to Investors and Venture Capitals health innovation projects of great impact and path, among which is the project of ARTHEx biotech S.L.

Fundación para la Innvación y la Prospectiva en Salud en España